Sign in

Private company

Ambrx Biopharma, Inc.

Ambrx Biopharma, Inc. is a biological products company.1 It is headquartered in La Jolla, California.1

Last updated Oct 21, 2026.

Overview

  • IndustryBiological Products, (No Diagnostic Substances)1
  • HeadquartersLa Jolla, California1
  • Business address10975 North Torrey Pines Road, La Jolla, Ca 920372
  • Filer category, Emerging growth company2

See how the biggest companies compare on our leaderboards

Corporate structure

Ambrx Biopharma, Inc. is part of a group headed by Johnson & Johnson. 460 entities, 73 countries on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Ambrx Biopharma, Inc.

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); subsidiaries listed in Exhibit 21 of annual reports filed with the SEC; subsidiaries, stakes and holdings from Wikidata (CC0); major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

Leadership

Who has led Ambrx Biopharma, Inc., and when. Pick a name to see everywhere that person has worked.

Chief financial officer

  1. Sonja Nelson2023–2024

Chief operating officer

  1. Andrew Aromando2023–2024
2025
Board members and other officers (5)

Former names

  • New Ambrx Biopharma Inc.Aug 25, 2023 to Sep 15, 20232

Timeline

  1. Mar 12, 20248-K Executive or director change10
  2. Mar 7, 20248-K Ended a material agreement; Completed an acquisition or sale; Listing notice or transfer11
  3. Mar 6, 20248-K Shareholder vote; Regulation FD disclosure12
  4. Feb 22, 20248-K Other events13
  5. Jan 8, 20248-K Entered a material agreement; Regulation FD disclosure14
  6. Dec 1, 20238-K Executive or director change15
  7. Oct 23, 20238-K Other events16
  8. Oct 16, 20238-K Other events17

Filings

63 filings to the SEC since October 2021: 1 quarterly reports, 8 major events, 14 insider forms, 12 large holders, 28 other. The latest 20:

  1. Nov 14, 2024SC 13G/A EDGAR
  2. Mar 18, 202415-12G EDGAR
  3. Mar 12, 20248-K CURRENT REPORT EDGAR
  4. Mar 8, 2024EFFECT EDGAR
  5. Mar 8, 2024S-8 POS EDGAR
  6. Mar 8, 2024S-8 POS EDGAR
  7. Mar 8, 2024S-8 POS EDGAR
  8. Mar 8, 2024S-8 POS EDGAR
  9. Mar 8, 2024S-8 POS EDGAR
  10. Mar 7, 2024POS AM EDGAR
  11. Mar 7, 20248-K EDGAR
  12. Mar 7, 20244 EDGAR
  13. Mar 7, 20244 EDGAR
  14. Mar 7, 20244 EDGAR
  15. Mar 7, 20244 EDGAR
  16. Mar 7, 20244 EDGAR
  17. Mar 7, 20244 EDGAR
  18. Mar 7, 20244 EDGAR
  19. Mar 7, 20244 EDGAR
  20. Mar 6, 20248-K EDGAR

The 63 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

3 open-market trades by officers, directors and large owners since October 2021: 1 buys and 2 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Oct 27, 2023Nelson SonjaChief Financial OfficerSale12,778$9.82$125.5KForm 4
Oct 27, 2023O'Connor Daniel J.President and CEOSale50,012$9.82$491.1KForm 4
Oct 23, 2023Cormorant Asset Management, LP10% ownerBuy1,307,311$6.99$9.1MForm 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

SEC filer profile

How Ambrx Biopharma, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARAmbrx Biopharma, Inc.1
  • CIK0001990550
  • Employer ID (EIN)93-28921201
  • Filer status<br>emerging growth company1
  • Fiscal year endsDecember 311
  • Industry code (SIC)2836 Biological Products, (No Diagnostic Substances)1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business address10975 North Torrey Pines Road, La Jolla, CA 920371
  • Phone(858) 875-24001
  • Shares outstanding63,150,244 as of Nov 7, 202328
  • On EDGAR sinceAug 25, 20231
  • Filings77 in all: 4 (14), SC 13G/A (10), S-8 POS (9), 8-K (8), 144 (7), DFAN14A (4), CORRESP (3), DEFA14A (3)1
    All 23 form types

    EFFECT (3), SC 13G (2), UPLOAD (2), 10-Q (1), 15-12G (1), 25-NSE/A (1), 424B3 (1), 8-K12G3 (1), DEFM14A (1), POS AM (1), PREM14A (1), S-3 (1), S-4 (1), S-4/A (1), S-8 (1)

  • Latest filingsQuarterly report (10-Q) Nov 13, 2023
    Latest 8-K (8-K) Mar 12, 2024

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
    SEC EDGAROther events
  14. 14
  15. 15
  16. 16
    SEC EDGAROther events
  17. 17
    SEC EDGAROther events
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28